Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...4445464748495051525354...136137»
  • ||||||||||  D-penicillamine / Generic mfg.
    Journal:  D-penicillamine Induced Myasthenia Gravis in Wilson's Disease: A Case Report. (Pubmed Central) -  Jan 28, 2023   
    Therefore, clinicians should be more vigilant while prescribing patients with chelating drugs like D-penicillamine with regular monitoring of the new symptoms and keeping a very low threshold for the suspicion of myasthenia gravis. d-penicillamine; myasthenia gravis; pyridostigmine; Wilson's disease.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech
    REFRACTORY MYASTHENIA GRAVIS (MG) IN THE SETTING OF COVID-19 VACCINATION () -  Jan 25, 2023 - Abstract #SCCM2023SCCM_2012;    
    This has surged during the COVID-19 pandemic especially with medications like hydroxychloroquine and azithromycin initially used to treat acute infections...She approached her baseline strength and was discharged on prednisone and mycophenolate mofetil...Our patient may have had low titers of pre-existing self-antigen to the AChR that were released upon administration of the BNT162b2 COVID-19 vaccine. However, this vaccine effect may represent a correlation; further studies are needed to infer causality.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    PEMBROLIZUMAB-INDUCED MYOCARDITIS WITH CONCOMITANT MYOSITIS AND HEPATITIS () -  Jan 25, 2023 - Abstract #SCCM2023SCCM_1764;    
    Clinicians caring for patients who receive ICIs should be vigilant about the broad toxicity profile of these agents, as early recognition and expert consultation is pivotal to avoid morbidity and mortality. If appropriate clinical response is not achieved with corticosteroids alone, additional immunomodulatory medications such as IVIg can be considered.
  • ||||||||||  atorvastatin / Generic mfg., mycophenolate mofetil / Generic mfg.
    MORE THAN MYALGIA: STATIN-INDUCED IMMUNE-MEDIATED NECROTIZING MYOPATHY () -  Jan 25, 2023 - Abstract #SCCM2023SCCM_1279;    
    Description: A 58-year-old female with recently diagnosed hyperlipidemia started on atorvastatin (40 mg) 2 months prior to presentation was admitted with 2 weeks of progressively worsening proximal muscle weakness and oropharyngeal dysphagia...Given the high specificity of this test, her presentation was ultimately deemed consistent with statin induced immune-mediated necrotizing myopathy, and she was started on Cellcept (MMF) and high-dose steroids...Myalgia without significant weakness are a common side effect and therapy includes discontinuing the offending agent. In the presence of severe weakness, statin induced immune-mediated necrotizing myopathy should be considered, as it could be detrimental and may require mechanical ventilation and treatment with immunosuppressants.
  • ||||||||||  Journal:  Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. (Pubmed Central) -  Jan 25, 2023   
    In the presence of severe weakness, statin induced immune-mediated necrotizing myopathy should be considered, as it could be detrimental and may require mechanical ventilation and treatment with immunosuppressants. Early cycles of intervention with EFT and early use of calcineurin inhibitors provides long-term benefits in terms of achieving therapeutic targets for generalised MG, regardless of clinical subtype.
  • ||||||||||  Journal, IO biomarker:  Iron metabolism in non-anemic myasthenia gravis patients: A cohort study. (Pubmed Central) -  Jan 23, 2023   
    In conclusion, MBZYQD can improve the immune function of the host by regulating the diversity, structure and function of the intestinal microbiota to treat myasthenia gravis. Iron metabolism parameters might be promising biomarkers for evaluating disease severity and guiding therapeutic decision in MG patients.
  • ||||||||||  Review, Journal:  Epigenetics of Thymic Epithelial Tumors. (Pubmed Central) -  Jan 22, 2023   
    With these aims, several researchers investigated the epigenetic profiles of TETs. In this manuscript, we narratively review the works investigating the deregulation of epigenetic mechanisms in TETs, highlighting the need for further studies combining genetic, epigenetic, and expression data to better characterize the different molecular subtypes and identify, for each of them, the most relevant epigenetic biomarkers of clinical utility.
  • ||||||||||  Journal:  WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1. (Pubmed Central) -  Jan 22, 2023   
    In conclusion, the biweekly WT1 Trio vaccine containing the WT1-332 helper T lymphocyte peptide induced more robust immune responses targeting WT1 than the weekly WT1-235 CTL peptide vaccine. Therefore, WT1-targeted immunotherapy may be a potential therapeutic strategy for rare cancers.
  • ||||||||||  Journal:  Neurology: what's new in 2022 (Pubmed Central) -  Jan 21, 2023   
    A new possibility of subcutaneous continuous levodopa administration gave promising result. Finally, numerous studies confirmed the efficacy and excellent tolerability of anti-CGRP antibodies.
  • ||||||||||  Enrollment open:  A Prospective, Single-Center Investigation of the da Vinci SP (clinicaltrials.gov) -  Jan 20, 2023   
    P=N/A,  N=15, Recruiting, 
    Finally, numerous studies confirmed the efficacy and excellent tolerability of anti-CGRP antibodies. Not yet recruiting --> Recruiting
  • ||||||||||  Lumevoq (lenadogene nolparvovec) / GenSight, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Literature Commentary. (Pubmed Central) -  Jan 19, 2023   
    JAMA Ophthalmol. 2022;140:1076-1083.
  • ||||||||||  Journal:  Ophthalmologic clinical features of ocular myasthenia gravis. (Pubmed Central) -  Jan 14, 2023   
    In addition, both horizontal and vertical diplopia was significantly higher in the group with AchR Ab titer > 5.0 than that in the group with AchR Ab titer < 5.0 (P = .041). After excluding cranial nerve palsy, if there is ptosis and diplopia, especially vertical diplopia, the possibility of OMG should be considered.
  • ||||||||||  Journal:  Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis. (Pubmed Central) -  Jan 14, 2023   
    In the NSG-MG model, the treatment reduced pathogenic Th17 cell population and expression of genes involved in eGC stabilization and B-cell development in human MG thymus biopsies. Altogether, these data suggest that a therapy targeting IL-23p19 may promote significant clinical ameliorations in AChR MG disease due to concomitant beneficial effects on the thymus and skeletal muscle defects.
  • ||||||||||  Trial completion date, Trial primary completion date:  The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis (clinicaltrials.gov) -  Jan 13, 2023   
    P=N/A,  N=144, Not yet recruiting, 
    Disease characteristics including exacerbation and treatment history may be an indicator of future high costs. Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Aug 2023 --> Mar 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Metastases:  A Case of Metastatic Ureteral Cancer Treated with Pembrolizumab without Relapse of Ocular Myasthenia Gravis (Pubmed Central) -  Jan 12, 2023   
    We changed the regimen to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) therapy and the cycle was completed without complications...Myasthenia gravis is a possible immune-related adverse event of pembrolizumab, However, there have been few reports on the successful treatment with this agent in patients with previously diagnosed myasthenia gravis. We report, here, a case of metastatic ureteral carcinoma safely treated with pembrolizumab without relapse of ocular myasthenia gravis.
  • ||||||||||  AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
    Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review. (Pubmed Central) -  Jan 11, 2023   
    The role of thymectomy in the acute setting merits further analysis. In this paper, Through the report and follow-up analysis of this case, this paper recognizes that the early correct understanding and evaluation of this fulminant and fatal irAEs and the reasonable treatment of patients are very important for the prognosis of patients.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Spikevax (elasomeran) / Moderna
    Review, Journal:  The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review. (Pubmed Central) -  Jan 10, 2023   
    COVID-19 vaccines may cause new-onset or worsening of MG in a small proportion of population. Large-scale, multicenter, prospective, and rigorous studies are required to verify their safety.
  • ||||||||||  Journal:  Maximal Thymectomy via Mini Sternotomy with Pleural Preservation. (Pubmed Central) -  Jan 10, 2023   
    Conclusions  Mini sternotomy allows maximal removal of thymus through a less invasive approach and is associated with a significantly smoother postoperative course, less overall complications, and good clinical outcome. It is a simple technique that can be performed by any thoracic and surgical oncologists especially in Indian subcontinent where facilities of video-assisted thoracoscopic surgery and robotic video-assisted thoracoscopic surgery are not available in all areas and are expensive.
  • ||||||||||  Votrient (pazopanib) / Novartis, Welireg (belzutifan) / Merck (MSD)
    Review, Journal:  Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis. (Pubmed Central) -  Jan 9, 2023   
    The present study aims to outline the fundamental mechanisms that link VHL disease and immune disorders, as well as to explore the details of the overlap between VHL disease and myasthenia gravis (MG) pathogenetic pathways. As a result, MG becomes a paradigm for autoimmune disorders that might be related with VHL disease.
  • ||||||||||  Review, Journal:  The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder. (Pubmed Central) -  Jan 8, 2023   
    The most severe form of statin-related myotoxicity is immune-mediated necrotizing myopathy. Management of hypercholesterolemia in patients with NMDs include treating modifiable factors, consideration of toxicity risk of statin, use of non-statin lipid lowering agents, noting possible drug interactions, and careful monitoring.